Programma finale completo - SIF - Università degli Studi di Torino
Programma finale completo - SIF - Università degli Studi di Torino
Programma finale completo - SIF - Università degli Studi di Torino
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Farmacologia clinica e sperimentazione clinica dei farmaci<br />
Poster 225 – 240<br />
225. Quality of life of pe<strong>di</strong>atric patients with attention deficit hyperactivity <strong>di</strong>sorder and<br />
oppositive defiant <strong>di</strong>sorder: an italian double-blind placebo-controlled study with<br />
atomoxetine<br />
Dell’Agnello Grazia 2 , Curatolo P. 1 , Mancini F. 2<br />
1 Neuropsychiatria Infantile Clinica Sant’Alessandro, Rome, Italy; 2 Eli Lilly Italia<br />
226. Evening and early morning administration of atomozetine in ADHD children: a<br />
comparison<br />
Dell’Agnello Grazia 4 , Kelsey D. 1 , Sutton V. 1 , Lewis D. 2 , Schuh K. 1 ; Sumner C. 1 , Quintana H. 3 ,<br />
Fre<strong>di</strong>ani S. 4 , Rossi A. 4<br />
1 Lilly Research Laboratories,In<strong>di</strong>anapolis,IN;<br />
2 Monarch Me<strong>di</strong>cal Research,Norfolk,VA;<br />
3 Louisiana State University Health Science Center,New Orleans,LA; 4 Eli Lilly Italia<br />
227. Safety and tolerability of duloxetine in the treatment of major depressive <strong>di</strong>sorder:<br />
analysis of pooled data from eight placebo-controlled clinical trials<br />
Mancini Michele, Barraco A., Rossi A.<br />
Eli Lilly Italia S.p.A.<br />
228. The new antidepressant duloxetine: car<strong>di</strong>ovascular effects<br />
Mancini Michele, Barraco A., Rossi A.<br />
Eli Lilly Italia S.p.A.<br />
229. The management of bipolar mania: a national survey of baseline data from the<br />
emblem study<br />
Mancini Michele 2 , Bellantuono C. 1 , Rossi A. 2 , Barraco A. 2 , Goetz I. 3 , for the Italian EMBLEM<br />
study group<br />
1 Department of Me<strong>di</strong>cine and Public Health, Section of Psychiatry and Clinical Psychology,<br />
University of Verona, Italy; 2 Eli Lilly Italia S.p.A. for the Italian EMBLEM study group; 3 Eli Lilly<br />
and Company, Windlesham, UK<br />
141<br />
230. European mania in bipolar longitu<strong>di</strong>nal evaluation of me<strong>di</strong>cation (emblem) study:<br />
results of the acute 12-week phase in Italy by regional location (north, centre and<br />
south)<br />
Mancini Michele 1 , Rossi A. 1 , Barraco A.1, Goetz I. 2 , for the Italian EMBLEM study group<br />
1 Eli Lilly Italia S.p.A.; 2 Eli Lilly and Company, Windlesham, UK<br />
231. Effectiveness of antipsychotic treatment in outpatients with schizophrenia: 36-<br />
month results from the schizophrenia outpatients health outcomes (SOHO) study<br />
Scatigna Marco (3) , Novick Diego (1) , Haro Josè M. (2) , Brown James (1) , Suarez Diego (2) , Rossi<br />
Andrea (3) , Fre<strong>di</strong>ani Sonia (3) , Ratcliffe Mark C. (1) , and the SOHO Study Group (4)<br />
(1) Eli Lilly and Company, Windlesham, UK (2) Unità ricerca e sviluppo, San Joan de Deu-SSM,<br />
Sant Boi, Barcellona, Spagna (3) Eli illy Italia S.p.A. (4) Alonso J (SP), Gasquet I (FR), Haro JM<br />
(SP) Jones PB (UK), Knapp M (UK), Lepine JP (FR), Naber D (DE), Slooff CJ (NL)<br />
232. Tolerability of outpatient antipsychotic treatment: 36-month results from the<br />
european schizophrenia outpatients health outcomes (soho) study<br />
Scatigna Marco (5) , Novick D. (1) , Haro Josè M. (2) , Suarez D. (2) , Bushe C. (3) , Lepine A. (4) , Rossi<br />
A. (5) , Fre<strong>di</strong>ani S. (5) , the SOHO Study Group (6)<br />
(1) Eli Lilly and Company, Windlesham, UK (2) Unità ricerca e sviluppo, San Joan de Deu-SSM,<br />
Sant Boi, Barcellona, Spagna (3) Eli Lilly and Company, Basingstoke, UK; (4) Hôpital Fernand<br />
Widal Parigi Cedex 10 (5) Eli Lilly Italia S.p.A. (6) Alonso J (SP), Gasquet I (FR), Haro JM (SP)<br />
Jones PB (UK), Knapp M (UK), Lepine JP (FR), Naber D (DE), Slooff CJ (NL)<br />
pag_dx.indd 1 30/05/2007 5.57.26